


CLAIMS

1. An agent for treating visual cell function disorder comprising an interleukin 2 inhibitor as an active ingredient.

5 2. The agent of claim 1, wherein the interleukin 2 inhibitor is a macrolide compound or a cyclosporin.

3. The agent of claim 2, wherein the macrolide compound is a tricyclo compound (I) of the following formula



10 wherein adjacent pairs of R^1 and R^2 , R^3 and R^4 , and R^5 and R^6 each independently
 a) consist of two adjacent hydrogen atoms, wherein R^2 is optionally alkyl, or
 b) form another bond optionally between carbon atoms binding with the
 members of said pairs ;

15 R^7 is hydrogen atom, hydroxy, protected hydroxy, or alkyloxy, or optionally form
 oxo with R^1 ;

R^8 and R^9 each independently show hydrogen atom or hydroxy ;

R^{10} is hydrogen atom, alkyl, alkyl substituted by one or more hydroxy, alkenyl,
 alkenyl substituted by one or more hydroxy or alkyl substituted by oxo ;

20 X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group
 of the formula $-\text{CH}_2\text{O}-$;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group
 of the formula $\text{N}-\text{NR}^{11}\text{R}^{12}$ or $\text{N}-\text{OR}^{13}$;

Art 14
R¹¹ and R¹² each independently show hydrogen atom, alkyl, aryl or tosyl ;
R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²² and R²³ each independently show hydrogen atom or alkyl ;

R²⁴ is a ring that is optionally substituted and optionally contain one or more
5 hetero atom(s) ; and

n is 1 or 2,

wherein Y, R¹⁰ and R²³ optionally show, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, the heterocyclic group being optionally substituted by one or more group(s) selected from the group consisting of alkyl, hydroxy, alkyloxy, benzyl, a group of the formula -CH₂Se(C₆H₅), and alkyl substituted by one or more hydroxy,

or a pharmaceutically acceptable salt thereof.

4. The agent of claim 2 or claim 3, wherein the macrolide compound is FK506.

5. The agent of any of claim 1 to claim 4, which is used for the treatment of retinopathy.

6. The agent of claim 5, wherein the retinopathy is ischemic retinopathy.

7. The agent of claim 6, wherein the ischemic retinopathy is diabetic retinopathy.

8. The agent of any of claim 1 to claim 7, which is in the form of a preparation for local administration to the eye.

9. A method for treating visual cell function disorder, comprising administering an effective amount of interleukin 2 inhibitor to a subject in need of the treatment of visual cell function disorder.

10. Use of interleukin 2 inhibitor for the production of a pharmaceutical composition for the treatment of visual cell function disorder.